Amino Technologies (AMO LN) FY’17 in line with cash well ahead of expectations | Consort Medical (CSRT LN) In line interims, still waiting for a catalyst | First Derivatives (FDP LN) First investment by FD/BGF strategic partnership | FreeAgent (FREE LN) Emerging banking channel; Practice growth tempers | Gateley (GTLY LN) In line interim results, seasonally stronger H2 expected | iomart Group (IOM LN) Solid interims with bolt-ons establishing eCommerce presence | mporium Group (MPM LN) Seven figure contract win for FWM business | Northgate (NTG LN) Caution around disposal profits, but attractively valued | Oxford BioMedica (OXB LN) Upgrade to Buy as confidence increases | PCI-PAL (PCIP LN) New contracts and positive trading update | Realm Therapeutics (RLM LN) Phase II trial start in Atopic Dermatitis | Victrex (VCT LN) Strong prelims, special dividend ahead of expectations | WYG (WYG LN) Tackling H1challenges, targeting a return to growth